Literature DB >> 29422972

Detection of circulating tumor cells in pulmonary venous blood for resectable non-small cell lung cancer.

Chao Lv1, Bingtian Zhao1, Limin Wang2, Panpan Zhang1, Yuanyuan Ma1, Yuzhao Wang1, Nan Wu1, Ying Wu3, Yue Yang1.   

Abstract

Intraoperative manipulation causes circulating tumor cell (CTC) shedding into the blood and accelerates metastasis in non-small cell lung cancer (NSCLC). The present study was conducted to assess the degree of dissemination resulting from surgery and to explore the biological features of CTCs. In patients with NSCLC who underwent complete resection, the pulmonary vein (PV) was isolated and stapled following thoracotomy. The number of CTCs retained per 7.5 ml PV blood (CTC-PV) and peripheral blood were detected. Following hematopoietic cell depletion, a xenograft assay was performed using the CTC-PV. A total of 32 consecutive patients were enrolled in the study, the majority of whom had CTCs in their PV blood (n=29, 90.6%). Circulating tumor microemboli (CTM) were identified in 12 patients (37.5%). The CTC-PV and CTM-PV counts were positively correlated with tumor size (P=0.012 and P=0.028, respectively). Patients with small tumors (<3.0 cm) also had considerable CTC-PV and CTM-PV. A total of 8 patients received platinum-based chemotherapy prior to surgery. The CTC-PV and CTM-PV counts in patients with partial response were significantly lower than those in patients with stable disease or who did not receive induction therapy (P=0.025 and P=0.044, respectively). The enriched CTC-PV from 3 patients were injected into 3 immunodeficient mice, and 1 mouse developed a xenograft tumor. To conclude, the present study indicates that intraoperative manipulation contributes to the hematogenous dissemination of tumorigenic CTCs and CTM. Lobectomy is recommended for lung cancer of any tumor size and stage according to oncological principles, in addition to ligating the PV, if possible, prior to any other treatment.

Entities:  

Keywords:  circulating tumor cell; circulating tumor microemboli; hematogenous spread; lobectomy; non-small cell lung cancer; pulmonary vein ligation

Year:  2017        PMID: 29422972      PMCID: PMC5772954          DOI: 10.3892/ol.2017.7405

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer.

Authors:  Masaki Hashimoto; Fumihiro Tanaka; Kazue Yoneda; Teruhisa Takuwa; Seiji Matsumoto; Yoshitomo Okumura; Nobuyuki Kondo; Noriaki Tsubota; Tohru Tsujimura; Chiharu Tabata; Takashi Nakano; Seiki Hasegawa
Journal:  Interact Cardiovasc Thorac Surg       Date:  2014-03-11

2.  Novel approach for detection of isolated tumor cells in pulmonary vein using negative selection method: morphological classification and clinical implications.

Authors:  Soichiro Funaki; Noriyoshi Sawabata; Tomoyuki Nakagiri; Yasushi Shintani; Masayoshi Inoue; Yoshiki Kadota; Masato Minami; Meinoshin Okumura
Journal:  Eur J Cardiothorac Surg       Date:  2011-01-07       Impact factor: 4.191

3.  Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.

Authors:  Apar Pataer; Neda Kalhor; Arlene M Correa; Maria Gabriela Raso; Jeremy J Erasmus; Edward S Kim; Carmen Behrens; J Jack Lee; Jack A Roth; David J Stewart; Ara A Vaporciyan; Ignacio I Wistuba; Stephen G Swisher
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

4.  Lung cancer: New biological insights and recent therapeutic advances.

Authors:  Suresh S Ramalingam; Taofeek K Owonikoko; Fadlo R Khuri
Journal:  CA Cancer J Clin       Date:  2011-02-08       Impact factor: 508.702

5.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.

Authors:  Jian-Mei Hou; Matthew G Krebs; Lee Lancashire; Robert Sloane; Alison Backen; Rajeeb K Swain; Lynsey J C Priest; Alastair Greystoke; Cong Zhou; Karen Morris; Tim Ward; Fiona H Blackhall; Caroline Dive
Journal:  J Clin Oncol       Date:  2012-01-17       Impact factor: 44.544

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  The sequence of vessel interruption during lobectomy for non-small cell lung cancer: is it indeed important?

Authors:  Yael Refaely; Siegal Sadetzki; Angela Chetrit; David A Simansky; Michael Paley; Baruch Modan; Alon Yellin
Journal:  J Thorac Cardiovasc Surg       Date:  2003-06       Impact factor: 5.209

8.  Tumour cells in the tumour draining vein of patients with non-small cell lung cancer: detection rate and clinical significance.

Authors:  Wulf Sienel; Rita Seen-Hibler; Wolf Mutschler; Klaus Pantel; Bernward Passlick
Journal:  Eur J Cardiothorac Surg       Date:  2003-04       Impact factor: 4.191

9.  The sequence of vessel ligation affects tumor release into the circulation.

Authors:  Y Kurusu; J Yamashita; N Hayashi; S Mita; N Fujino; M Ogawa
Journal:  J Thorac Cardiovasc Surg       Date:  1998-07       Impact factor: 5.209

10.  Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model.

Authors:  Zhuo Zhang; Hiroe Shiratsuchi; Jules Lin; Guoan Chen; Rishindra M Reddy; Ebrahim Azizi; Shamileh Fouladdel; Andrew C Chang; Lin Lin; Hui Jiang; Meghna Waghray; Gary Luker; Diane M Simeone; Max S Wicha; David G Beer; Nithya Ramnath; Sunitha Nagrath
Journal:  Oncotarget       Date:  2014-12-15
View more
  8 in total

1.  Wedge Resection of Tumor Before Lobectomy for Lung Cancer Could Be a No-touch Isolation Technique.

Authors:  Motoaki Yasukawa; Noriyoshi Sawabata; Takeshi Kawaguchi; Shigeki Taniguchi
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

Review 2.  Tuberculosis: mother of thoracic surgery then and now, past and prospectives: a review.

Authors:  Tamas F Molnar
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Prognostic Role of Circulating Tumor Cells in the Pulmonary Vein, Peripheral Blood, and Bone Marrow in Resectable Non-Small Cell Lung Cancer.

Authors:  Jeong Moon Lee; Woohyun Jung; Sungwon Yum; Jeong Hoon Lee; Sukki Cho
Journal:  J Chest Surg       Date:  2022-06-05

Review 4.  Magnetically driven microfluidics for isolation of circulating tumor cells.

Authors:  Laan Luo; Yongqing He
Journal:  Cancer Med       Date:  2020-04-23       Impact factor: 4.452

Review 5.  Possible role of circulating tumor cells in early detection of lung cancer.

Authors:  Cristina Poggiana; Elisabetta Rossi; Rita Zamarchi
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 3.005

6.  Circulating tumor cells in the pulmonary vein increase significantly after lobectomy: A prospective observational study.

Authors:  Xinchun Duan; Yujie Zhu; Yong Cui; Zhenrong Yang; Shijie Zhou; Yi Han; Daping Yu; Ning Xiao; Xiaoqing Cao; Yunsong Li; Shuku Liu; Zitong Wang; Wen Zhang; Lin Feng; Kaitai Zhang; Jianzhong Shou; Zhidong Liu; Shaofa Xu
Journal:  Thorac Cancer       Date:  2018-12-04       Impact factor: 3.500

Review 7.  Tumor-proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells.

Authors:  Etienne Buscail; Laurence Chiche; Christophe Laurent; Véronique Vendrely; Quentin Denost; Jérôme Denis; Matthieu Thumerel; Jean-Marc Lacorte; Aurélie Bedel; François Moreau-Gaudry; Sandrine Dabernat; Catherine Alix-Panabières
Journal:  Mol Oncol       Date:  2019-07-25       Impact factor: 6.603

8.  Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer.

Authors:  Yang Hong; Jiahui Si; Jie Zhang; Ying Xiong; Jianzhi Zhang; Peter Ping Lin; Jian Fang; Yue Yang; Chao Lv; Yuanyuan Ma
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.